Hematology Oncology

Geo Espinosa on Prostate Cancer for Natural Oncology Masterclass II

Michael Traub on Melanoma for Oncology Masterclass II

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. 

Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases


Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

Federal Practitioner recently talked with Dr. Adrian Weistner and Dr. Mark Roschewski of the National Institutes of Health. Both doctors will be presenting during the September 12, 2014 Lymphoma Mini-Symposium and panel discussion that kicks off this weekend’s 2014 AVAHO Meeting in Portland, Oregon

Treatments for Chronic Lymphocytic and Mantel Cell Luekemia

Roy S. Herbst MD PhD is Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center.

This is an excerpt from an interview he gave at the 2014 annual meeting of the Society for Immunotherapy of Cancer.

Dr Roy Herbst on Lung Cancer Immunotherapy

"Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy"

The research team’s analyses revealed ultra-hypermutation, defined as greater than 100 mutations per megabase, in this patients cancer, which was further characterized by the presence of three distinct mutational signatures including UV radiation and APOBEC signatures.

Truncal alterations, defined as being present in all clonal tumor cell populations, in this patients cancer include point mutations in TP53 and CDKN2A and amplifications of c-KIT and APOBEC3A-H, which are likely driver mutations.

Dr. Sameek Roychowdhury from the Department of Internal Medicine, Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA said, "Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare malignancy of dendritic cell origin with approximately 100 cases reported to date"

Localized IDCS constitutes 47% of cases and manifests as painless lymphadenopathy, most commonly involving the cervical and axillary nodes.

Isolated extra-nodal disease occurs in 25% of cases, involving the liver, lung, spleen, bone marrow and gastrointestinal tract .

Distant metastases occur in 39% of cases and most frequently involved lymph nodes, lung, liver and bone marrow .

Here they performed whole exome sequencing of multiple tumors obtained through rapid research autopsy of a patient with metastatic IDCS. In August 2016, the patient underwent modified radical right neck dissection and partial submandibular gland excision with one level I lymph node demonstrating complete tumor involvement and suspicious for extranodal extension; remaining lymph nodes from levels II, III and IV were negative for tumor infiltration.

In the future, it will be important to study additional patients with this and other rare cancers with hypermutation.

The Roychowdhury research team concluded, “Finally, the broader clinical implication of our results is that although patients with hypermutated cancer, originating from either somatic or germline genomic aberrations, are more likely to benefit from checkpoint inhibition, research is still needed to stratify these patients to maximize therapeutic efficacy and identify the different genetic determinants of primary or acquired resistance to immunotherapy.”

Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=26352&path%5B%5D=82077
 
Correspondence to - Sameek Roychowdhury email: Sameek.Roychowdhury@osumc.edu

Keywords - tumor heterogeneity, research autopsy, hypermutation
 
About Oncotarget
 
Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology, including Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes among others.
 
Oncotarget is published by Impact Journals LLC.
 
To learn more about Oncotarget, please visit http://www.ImpactJournals.com

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

Oncotarget Audio Interview with Sameek Roychowdhury & Hui-Zi Chen

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Oncotarget Audio Interview with Sameek Roychowdhury & Hui-Zi Chen

Oncotarget Podcast